Cargando…

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

BACKGROUND: Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic myeloid leukemias and 30 myeloproliferative neoplasms), all...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimpinelli, Fulvia, Marchesi, Francesco, Piaggio, Giulia, Giannarelli, Diana, Papa, Elena, Falcucci, Paolo, Pontone, Martina, Di Martino, Simona, Laquintana, Valentina, La Malfa, Antonia, Di Domenico, Enea Gino, Di Bella, Ornella, Falzone, Gianluca, Ensoli, Fabrizio, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, Mengarelli, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128283/
https://www.ncbi.nlm.nih.gov/pubmed/34001183
http://dx.doi.org/10.1186/s13045-021-01090-6